Aducanumab: Appropriate Use Recommendations Update

Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer’s disease or mild AD dementia. Aducanumab Appropriate Use Recommendations (AURs) have been published and have helped guide best practices for use of aducanumab. As real...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, J., Rabinovici, G.D., Atri, A., Aisen, P., Apostolova, L.G., Hendrix, S., Sabbagh, M., Selkoe, D., Weiner, M., Salloway, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169517/
https://www.ncbi.nlm.nih.gov/pubmed/35542993
http://dx.doi.org/10.14283/jpad.2022.34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169517/
https://www.ncbi.nlm.nih.gov/pubmed/35542993
http://dx.doi.org/10.14283/jpad.2022.34

Ejemplares similares